Delestrogen (Estradiol valerate injection) is commonly used to help with clinical situations driven by hormonal needs. It plays a role in managing symptomatic relief across domains where additional symptomatic support is needed.

---

What Delestrogen Treats: Main Uses and Benefits

This therapy is commonly used to help with symptom clusters that may become intense or disruptive associated with menopause. The therapeutic applications are relevant for easing moderate to severe vasomotor symptoms, such as frequent and intense hot flashes and night sweats, and localized symptoms of Genitourinary Syndrome of Menopause (GSM), like vaginal dryness and painful intercourse (dyspareunia). It is also relevant in conditions characterized by pronounced hormonal imbalance, such as hypogonadism, surgical castration (oophorectomy), or primary ovarian failure (POI). In a separate therapeutic domain, Delestrogen is applied in addressing palliative support for advanced androgen-dependent carcinoma of the prostate.

“This therapy assists with maintaining functional stability and supports the patient during difficult episodes by easing distress.”

Quick Fact: Relief for Vasomotor and Genitourinary Symptoms

Delestrogen contributes to supportive relief by helping to reduce the burden of symptoms that interfere with daily functioning, such as sudden hot flashes, and assists with maintaining comfort by addressing symptoms related to localized tissue atrophy. In all applications, it contributes to easing the overall symptom load in conditions where hormonal support is required.

Regulatory References

1. FDA Drug Label for Delestrogen

Official Population Eligibility for Delestrogen (Estradiol Valerate)

The population eligibility for Delestrogen is strictly defined by regulatory documents, listing specific groups for whom use is allowed, restricted, or contraindicated.

Populations Permitted to Use

Use is officially allowed for females experiencing moderate to severe vasomotor or vulvar/vaginal symptoms of menopause, and for treating estrogen deficiency due to hypogonadism, castration, or primary ovarian failure. It is also indicated for the palliative treatment of advanced androgen-dependent carcinoma of the prostate.

Absolute Contraindications

Delestrogen is strictly contraindicated in patients with a history of or active arterial or venous thromboembolic disease (e.g., DVT, PE, stroke, or myocardial infarction). Use is also prohibited in patients with known or suspected estrogen-dependent neoplasia, including a history of breast cancer, as well as those with active liver dysfunction or disease, undiagnosed abnormal genital bleeding, or known pregnancy.

Restricted and Non-Recommended Use

Population Group	Regulatory Status
Pregnancy	Contraindicated
Lactation	Not recommended (passes into breast milk)
Pediatric Use	Not indicated for children or adolescents
Intact Uterus	Use requires consideration of concomitant progestin therapy
Geriatric (65+)	Clinical experience is limited

For patients facing major surgery or prolonged immobilization, the medicine must be discontinued 4 to 6 weeks beforehand due to associated risk.

The documented interaction profile for Delestrogen is principally structured around substances that modify the body's processing of estradiol. The active ingredient is metabolized through the Cytochrome P450 3A4 (CYP3A4) hepatic enzyme pathway.

Pharmacokinetic and Substance Interactions

Medicines classified as CYP3A4 inducers, such as rifampin, carbamazepine, and phenobarbital, along with the herbal product St. John’s Wort, are officially documented to reduce the plasma concentration of estrogens, an outcome that may result in decreased therapeutic effects. Conversely, CYP3A4 inhibitors, including ketoconazole, ritonavir, erythromycin, clarithromycin, and grapefruit juice, can increase estradiol exposure, which may result in an increased potential for side effects. Acute ingestion of alcohol is also noted in regulatory documents to increase circulating estradiol levels by up to three-fold.

Procedural and Pharmacodynamic Constraints

A mandatory procedural constraint requires the medicine to be discontinued for at least four to six weeks before any surgery or period of prolonged immobilization associated with an increased risk of thromboembolism. Delestrogen is also documented to increase thyroid-binding globulin levels, necessitating that patients receiving Thyroid Hormone Replacement Therapy may require an adjustment to the dose of their replacement medication. A population-specific consideration notes that patients with pre-existing hypertriglyceridemia carry a documented risk of severe plasma triglyceride elevation.

Delestrogen (estradiol valerate) is a prodrug that is hydrolyzed in vivo to its active form, estradiol, which functions as an estrogen receptor agonist. The mechanism of action is mediated by binding to the nuclear Estrogen Receptors (ERs), specifically ERalpha and ERbeta, present in target cells. The estradiol-ER complex translocates to the nucleus where it binds to specific hormone-response elements (HREs) on the DNA. This binding event initiates or suppresses the transcription of adjacent genes, thereby modulating the synthesis of various proteins and shaping subsequent cellular processes.

Downstream, this activity influences key endocrine feedback loops, notably the Hypothalamic-Pituitary-Gonadal (HPG) axis. Elevated estradiol levels suppress the signaling sequences that control the release of gonadotropins (LH and FSH), resulting in a net reduction of their secretion. Furthermore, estradiol-mediated gene regulation acts on specific tissue systems, such as bone, where it modulates the balance of bone turnover by inhibiting osteoclast-mediated bone resorption and regulating signaling patterns in urogenital tissues.

How to Use Delestrogen: Official Administration Guidelines

The following instructions summarize the official requirements for administering Delestrogen (Estradiol Valerate Injection, USP).

Administration Requirements

Domain	Official Instruction
Route of Administration	Must be administered by intramuscular (IM) injection only.
Injection Site	Administer deeply into the upper, outer quadrant of the gluteal muscle following usual injection precautions.
Preparation	Visually inspect the solution for particulate matter and discoloration. The solution is clear, colorless to pale yellow. Use a dry needle and syringe for drawing up the dose to prevent cloudiness of the oil-based solution.
Aspiration	Before injecting, the plunger should be pulled back slightly (aspirated) to ensure the needle is not in a blood vessel.

Dosing and Treatment Duration

Domain	Official Instruction
Dosage Principle	The dosage should be the lowest effective dose that provides symptom control for the approved indication.
Duration Principle	Estrogen therapy should be used for the shortest period possible consistent with treatment goals.
Reassessment	The need for continued therapy should be reassessed periodically, typically at 3-month to 6-month intervals, to determine if treatment is still necessary.
Progestin Consideration	For a postmenopausal woman with a uterus, the addition of a progestin should be considered to reduce the risk of endometrial changes.

These guidelines establish a strict parenteral administration protocol, requiring deep intramuscular injection into a specific site to ensure proper medication release and absorption. The duration principles mandate that physicians must use the smallest effective dose for the shortest time, with regular reassessment to confirm the continued need for the drug, structuring the therapy as a periodic, monitored treatment regimen.

Research Evidence / Overview of Studies for Delestrogen

---

Evidence for Managing Moderate to Severe Menopausal Symptoms

Research has explored the use of systemic estrogen replacement therapy for moderate to severe vasomotor symptoms (hot flashes and night sweats) and Genitourinary Syndrome of Menopause (GSM), focusing on the types of outcomes measured in these studies. The evidence base includes short-term Randomized Controlled Trials (RCTs) and systematic reviews. Studies monitored patient-reported outcomes describing perceived discomfort, such as changes in the frequency and intensity of hot flashes, as well as outcomes related to systemic or functional imbalance, like measurements of the Vaginal Health Index (VHI) scores.

Findings describe patterns observed in the studies consistent with research protocols exploring symptom management. The available evidence primarily describes findings across the class of systemic estrogen replacement agents. What remains uncertain is the full extent of the evidence regarding the injectable route's particular impact on localized GSM symptoms, especially relative to data for localized therapies.

---

Evidence for Hormone Deficiency States

The medicine was studied for use in patients with estrogen deficiency resulting from conditions such as primary ovarian failure, hypogonadism, or surgical removal of the ovaries. The research framework consists of clinical trials, focusing on outcomes related to systemic or functional imbalance and restoration of hormone levels.

These studies monitored the ability of the therapy to restore and maintain physiological serum estradiol levels and track the resulting modulation of other reproductive hormones. Research describes that the administration was associated with measured changes in hormone levels and bone health markers, with findings contributing to the broader evidence landscape for estrogen replacement as a whole. Long-term data for endpoints like bone mineral density are often derived from the broader systemic estrogen evidence base, and sample sizes were modest in some studies focusing solely on the injectable formulation.

---

Research Gaps and What Remains Uncertain

The overall evidence quality varies across studies, and research highlights what is known—and what is still uncertain. Certainty remains low in areas where findings must be extrapolated from the comprehensive data collected for systemic estrogen as a class. Data for certain groups remain insufficient regarding the use of this injectable in patients with specific comorbidities, or when tracking outcomes over many years. The limited sample sizes mean that the results apply only to the populations studied and do not provide complete insight into the long-term profile when compared to newer hormone therapies administered by different routes.

Key Studies & References

1. Estrogen Therapy - StatPearls - NCBI Bookshelf (Indication and Formulation Overview)
2. Hormone Replacement Therapy (HRT) for Menopause - Cleveland Clinic (General Estrogen Use and Contraindications)
3. Prostate Cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (Estrogen Therapy Context)

Common questions about Delestrogen (FAQ)

Q: Can Delestrogen cause changes in weight?

A: Official product information states that Delestrogen has been associated with changes in weight. This can include either an increase or a decrease in body weight. This information is based on adverse reactions reported in regulatory documents.

Q: Why is Delestrogen available as an injection and not just a pill?

A: Delestrogen is supplied as an injectable solution because of its chemical design. The hormone is an ester derivative within an oil solution to allow it to release slowly after intramuscular injection. This formulation is intended to provide a continuous and sustained supply of estrogen in the body over a longer period.

Q: Is it common to feel tired when first starting Delestrogen?

A: Tiredness, or fatigue, is listed among the possible adverse reactions reported in the experience of using this drug. Official safety information also notes that unusual tiredness or weakness is cited as a symptom of potential overdose. Information regarding the specific frequency of tiredness is generally not detailed in patient-facing documentation.

Q: What does 'contraindication' mean in relation to Delestrogen use?

A: A contraindication is a medical term used in official documents to describe a specific condition or factor that strictly prohibits the use of a medicine. If a person has a contraindication, it means the medication is generally restricted from being used because it carries a documented risk of serious harm.

Q: What does the term 'Estradiol Valerate' mean?

A: Estradiol valerate is the active ingredient, which is a synthetic form of the naturally occurring hormone estradiol. The 'valerate' compound is a chemical group added to the estradiol. This structure is intended to allow the hormone to be slowly released into the body following the injection, thereby prolonging its action.

Q: What happens if Delestrogen is exposed to extreme heat or cold?

A: Official guidance emphasizes that Delestrogen must be stored at a controlled room temperature range, and official requirements specify that it should not be refrigerated. Storing the product outside of the recommended temperature range may compromise the chemical integrity and quality of the medicine. This is why careful storage is required to ensure the medication remains effective.

Q: Can Delestrogen be used by someone who has had a hysterectomy?

A: Yes, Delestrogen is indicated for conditions of estrogen deficiency, which can include those resulting from surgical removal of the ovaries and uterus (hysterectomy and oophorectomy). Official instructions note that for women who still have their uterus, the addition of a progestin therapy is a component required for consideration to manage certain risks associated with having a uterus.

Q: If I miss a dose of Delestrogen, what is generally suggested in the patient information?

A: Regulatory patient information does not provide specific self-management instructions for a missed dose. Official documentation directs users to contact their healthcare provider or pharmacist immediately to receive instructions or establish a new schedule.

Q: Is Delestrogen known to interact with common pain relievers like ibuprofen?

A: Official regulatory documents focus on known interactions involving substances that affect the liver enzyme CYP3A4. The prescribing information does not list a specific drug-drug interaction between estradiol valerate and common nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen.

Q: What specific ingredients are in Delestrogen, besides the active hormone?

A: The active ingredient is estradiol valerate. According to the official description, the medicine is supplied as a sterile solution in a base of sesame oil for intramuscular injection.

Q: How is Delestrogen different from estradiol patches?

A: Delestrogen is administered via intramuscular injection, a parenteral route designed for sustained release. Patches are a transdermal route, meaning the medicine is absorbed through the skin. Both methods are designed to avoid the initial processing of the drug by the liver, but they deliver the hormone with different absorption characteristics.

Q: Does Delestrogen affect blood pressure?

A: Yes, changes in blood pressure are listed in the official prescribing information as a potential side effect. This includes the possibility of blood pressure increasing.

Q: Can Delestrogen change mood or emotional state?

A: Official safety documents report that effects on emotional state and mood are possible. These reported adverse reactions include nervousness, irritability, and mental depression, among other mood disturbances.

Q: How long does Delestrogen stay in the body after an injection?

A: Due to the oil-based formulation, Delestrogen is designed to provide prolonged estrogenic action after administration. Regulatory information indicates that the therapeutic effect typically lasts for approximately two to three weeks following a single intramuscular injection.

Q: What are the symptoms of a serious allergic reaction to Delestrogen?

A: Serious hypersensitivity reactions, including anaphylaxis, are listed in official safety documents. Symptoms can include swelling of the face, lips, tongue, or throat, severe dizziness, or difficulty breathing.

Q: Are the side effects of Delestrogen different depending on the injection frequency?

A: Official safety information indicates that the risk of some adverse effects, particularly the risk of endometrial changes, is related to the duration of therapy and the dose of estrogen. The frequency of the injection is a factor used by the prescribing provider to manage the dose and duration of treatment.

Q: Is it possible for Delestrogen to interact with blood thinners?

A: Regulatory documents do not list a direct drug-drug interaction with common blood thinners. However, official warnings specify that estrogens are associated with an increased risk of thromboembolic events (blood clots), which requires caution and monitoring for any patient using blood thinners.

Q: Are vision changes ever reported with Delestrogen use?

A: Yes, visual disturbances and abnormal vision have been reported as adverse effects. Official warnings specify that discontinuation of the medication is specified in official warnings if a sudden partial or complete loss of vision occurs.

Q: Where can I find the official FDA patient information leaflet for Delestrogen?

A: The official FDA Patient Information Leaflet, sometimes called the Patient Package Insert, is a required document. The provision of this leaflet is a requirement of the dispensing process and is provided with every new prescription and refill.

How to Store and Dispose of Delestrogen

Storage Requirements

Delestrogen (estradiol valerate injection) must be stored at controlled room temperature, maintaining a range between 20 C and 25 C (68 F and 77 F). The medication should be kept in its original package to ensure it is protected from light. It is required that this product not be refrigerated.

To ensure safety, the vial must be stored out of the reach of children.

Disposal Instructions

Unused Delestrogen must be disposed of according to local guidelines for pharmaceutical waste. Used needles and syringes must be discarded immediately in a designated, puncture-proof sharps container to prevent injury and improper disposal.